Last reviewed · How we verify
Anthelios Sx (ECAMSULE)
Anthelios SX (ECAMSULE) is a small molecule drug in the ecamsule class, originally developed by L'Oréal and currently owned by the company. It was FDA approved in 2006 for the treatment of certain skin conditions. The commercial status of Anthelios SX is patented, and it is used to treat conditions such as sunburn and skin discoloration. Key safety considerations include potential skin irritation and allergic reactions. As a sunscreen, it works by absorbing or reflecting UV radiation to prevent damage to the skin.
At a glance
| Generic name | ECAMSULE |
|---|---|
| Drug class | ecamsule |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
| First approval | 2006 |
Approved indications
Common side effects
Key clinical trials
- Assessment of the Human Systemic Absorption of Sunscreen Ingredients (PHASE1)
- Oral Isotretinoin for Photoaging: Results of a Randomized Controlled Phase II Trial (PHASE2)
- Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma (PHASE4)
- Multi-Centre European Photopatch Test Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anthelios Sx CI brief — competitive landscape report
- Anthelios Sx updates RSS · CI watch RSS